Adverse medical consequences can arise from both antibiotic underdosing and overdosing of hospitalized patients. In the former case, patients receive an insufficient amount of antibiotic to effectively combat infection. In the latter, an overabundance of antibiotic may increase the risk of toxicity. However, the pharmacokinetics and pharmacodynamics of common antibiotics, such as piperacillin and ciprofloxacin, can exhibit substantial variability among hospitalized patients due to patient characteristics (e.g., body mass) or complications (e.g., organ failure) **. As a result, simple algorithmic dosing strategies (e.g., based on creatinine alone) can fail to ensure an appropriate level of antibiotic exposure.

For an individual patient, pharmacokinetic uncertianty can be reduced by measuring drug concentration in the blood over time. These data can be used to estimate current and past drug exposure, predict future drug exposure under alternative dosing strategies, and adjust the dose accordingly. The methods and software presented herein were designed to implement this process using prior information about pharmacokinetic heterogeneity in the target population and, if available for the individual, measurments of drug concentration in the blood over time. In order to impact clinical decision making, these tasks must be accomplished in real-time and account for (often substantial) statistical uncertainty.

We implement Bayesian methods using pharmacokinetic data from a prior study [cite] to provide posterior estimates of individual target attainment, measured as the fraction of the dosing period spent above a specified blood concentration threshold; usually a multiple of a minimum inhibitory concentration (MIC). The minimum inhibitory concentration is the amount of the drug required to suppress the offending microorganism. This particular summary of target attainment (denoted T > kMIC, where k is positive) is useful for antibiotics that have time-dependent effectiveness. Other summaries, such as the peak concentration, may be useful for antibiotics with concentration-dependent effectiveness. Due to significant pharmacokinetic heterogeneity, measures of statistical uncertainty about T > kMIC are critical for understanding response to treatment at the patient-specific level, and for clinical decision-making. We summarize this statistical uncertainty by computing and presenting 95% credible intervals for patient-specific estiamtes of T > kMIC. However, in order for these methods to be practicable, it is necessary that computation can occur in real time. Due to the computational intensity of exact methods (e.g., Markov chain Monte Carlo), we sought to identify statistical approximations that are both accurate with regard to quantification of statistical uncertainty (i.e., the effective level of the approximate credible interval closely matches the nominal level, 95%) while also being computationally feasible to implement with no significant delay (e.g., via a web application). We accomplish this by using a serie of statistical approximations paired with a web application that renders these techniques accessible to, for example, a practicing physician. We present assessments of the accuracy and computational efficiency for this approach.

1 Methods

1.1 Two-compartment model

The two-compartment pharmacokinetic model is expressed as a system of two ordinary differential equations as follows, where m_1 and m_2 are the masses of drug in the central and peripheral compartments, respectively.

$$\frac{dm_1}{dt} = -k_{10}m_1 - k_{12}m_1 + k_{21}m_2 + k_R$$

$$\frac{dm_2}{dt} = +k_{12}m_1 - k_{21}m_2$$

The concentration of drug in the central compartment is given by $c_1 = m_1/v_1$, where v_1 is the volume of the central compartment. The parameters k_{10} , k_{12} , k_{21} , and k_R are described in Table 1

To assess patient response to treatment by measuring target attainment, defined in this context to be the fraction of dosing window for which the concentration of piperacillin in the bloodstream is $64\mu g/mL$: four times the minimum inhibitory concentration (MIC) for piperacillin. We denote this statistic as $ft > 4 \times MIC$. Dosing for a patient needs to be enough that the concentration in the blood remains above the necessary threshold for suppression of the offending microorganism, yet not so high as to increase the risk of adverse

Parameter	Units	Description
k_{10}	h^{-1}	Elimination rate from central compartment
k_{12}	h^{-1}	Distribution rate from central to peripheral compartment
k_{21}	h^{-1}	Distribution rate from peripheral to central compartment
k_R	$g \cdot h^{-1}$	Infusion rate into central compartment
v_1	L	Volume of central compartment

Table 1: Two-compartment model parameter units (SI) and descriptions.

side effects including toxicity. Typically, a multiple of the minimum inhibitory concentration is used for such measurements, since drug concentration is attenuated in muscle tissue relative to the bloodstream.

We measure $ft > 4 \times MIC$ by calculating a simple proportion of the time during the dosing window above $64\mu g/mL$. By default, the method considers the conclusion of the full dosing window to be 12 hours after the end of the final infusion. If implementing this method with other medications, the limit of the dosing window may need to be altered based on drug-specific properties such as the rate of elimination. We use a bisection root-finding method to identify the times at which the patient's concentration-time curve crosses $64\mu g/mL$. Drug concentration increases if and only if the drug is actively being infused intravenously. Once the IV is removed, the drug concentration can only decrease. Thus, the adjacent time points at which one infusion ends and the next begins (and vice versa) are used as endpoints in the bisection process.

Time 0 is taken to be the time of first drug infusion. This assumes that the concentration of drug in the patient's body is $0\mu g/mL$ at time 0. A specific pharmacodynamic target is usually outlined. In this case where we are considering piperacillin, the target is $ft > 4 \times MIC > 0.5$, or at least half of the dosing window is spent above the desired threshold.

1.2 Bayes prediction model

Concentration measurements are modeled using a nonlinear regression method with additive error as follows:

$$c_{ij} = \eta_i(t_{ij}, \theta_i) + \epsilon_{ij}$$

In this expression, c_{ij} is the measured concentration for subject $i = 1 \dots n$ at time t_{ij} for $j = 1 \dots m_i$, $\eta_i(t_{ij}, \theta_i)$ is the two-compartment model solution for subject i at time t_{ij} given parameters $\theta_i = [k_{10i}, k_{12i}, k_{21i}, v_{1i}]$, and ϵ_{ij} represents i.i.d. random error with mean zero. By specifying the random error density function, say $f(\epsilon_{ij}, \sigma)$, the subject-specific likelihood function is

$$L_i(\theta_i, \sigma) = \prod_{j=1}^{m_i} f(c_{ij} - \eta_i(t_{ij}, \theta_i), \sigma).$$

Thus, given a prior distribution $\pi_0(\theta_i)$, the subject-specific posterior is proportional to $\pi_i(\theta_i, \sigma) \propto \pi_0(\theta_i, \sigma) L_i(\theta_i, \sigma)$. In the current context, f is taken as the normal density function with mean zero and standard deviation σ , and the prior distribution is generated to satisfy the following:

$$[\log \theta_i] \sim N_4(\mu_0, \Sigma_0) \tag{1}$$

$$[\log \sigma] \sim N_1(m_0, s_0) \tag{2}$$

where $N_4(\mu_0, \Sigma_0)$ represents the 4-variate normal distribution with mean μ_0 and covariance matrix Σ_0 for the pharmacokinetic parameters, and $N_1(m_0, s_0)$ represents the univariate normal distribution with mean m_0 and variance s_0 . The prior distribution for the PK parameters represents our prior knowledge about the PK heterogeneity for a particular drug in a target population. Thus, the values of the prior hyperparameters should be carefully selected for the task at hand. In the current context, and by default, the hyperparameters are specified to correspond with estimates that arose from a study of piperacillin pharmacokinetics in a hospitalized, critically ill population. The particular values are listed in an appendix.

Due to the nonlinearity of the two-compartment model, the posterior distribution does not take a familiar form, and posterior summaries must be approximated. In particular, we sought to compute 95% credible bands for subject-specific concentration-time curves, and for a specific summary of the curve ($ft > 4 \times MIC$). Monte Carlo techniques are often used to approximate these quantities. However, because these posterior summaries are presented in a web application in real time, we sought alternatives that were less computationally intensive and deterministic. Implementation of Laplace and delta method approximations allow for rapid computation of posterior estimates.

We consider several possible types of intervals for $ft > 4 \times MIC$: logit-transformed, probit-transformed, and untransformed intervals. Logit- and probit-transformed intervals restrict the computed confidence interval boundaries to be between 0 and 1. Untransformed intervals can yield bounds above 1, in which case the upper confidence limit is truncated at 1. The untransformed 95% credible interval is computed as $\hat{\theta} \pm z_{0.975}SE(\hat{\theta})$. Gradients for the transformed intervals are computed using the delta method.

1.2.1 Laplace approximation

We first considered a method that makes use of two approximations. The first is a Laplace approximation to the subject-specific posterior density, and the second is a first order Taylor approximation of the target summary (i.e., the 'delta method'). The Laplace approximation is given as follows

$$\pi_i(\log \theta_i, \log \sigma) \approx N(\lceil \log \hat{\theta}_i, \log \hat{\sigma} \rceil, \lceil -H \rceil^{-1})$$

where $[\log \hat{\theta}_i, \log \hat{\sigma}]$ is the posterior mode and $H_{\hat{\theta}_i}$ is the posterior Hessian with respect to $[\log \theta_i, \log \sigma]$ evaluated at the posterior mode. The second approximation makes use of the delta method, such that a posterior functional $h(\log \theta_i)$ has an approximate normal distribution. In the present context, $h(\log \theta_i)$ represents the logit of the fraction of the dosing period in which the concentration of drug exceeds a spedified value. The first-order Taylor expansion of $h(\log \theta_i)$ is

$$h(\log \theta_i) \approx h(\log \hat{\theta_i}) + G^T(\log \theta_i - \log \hat{\theta_i}),$$

where G is the gradient of $h(\log \theta_i)$ with respect to $[\log \theta_i, \log \sigma]$ evaluated at the posterior mode. Thus, given that $[\log \theta_i, \log \sigma]$ has an approximate normal distribution, the same is true for $h(\log \theta_i)$:

$$h(\log \theta_i) \sim N(h(\log \hat{\theta_i}), G^T[-H]^{-1}G).$$

An approximate $(1-\alpha) \cdot 100\%$ credible interval for $h(\log \theta_i)$ is thus given by the $\alpha/2$ and $(1-\alpha)/2$ quantiles of the approximate posterior distribution for $h(\log \theta)$. This method is computationally elegant, since the posterior Hessian and posterior mode can be computed simultaneously by most optimization software routines (e.g., the R function 'optim'). Indeed, this method usually has the smallest computational burden (i.e., number of likelihood evaluations) among the three methods considered here.

1.3 Evaluation of approximation method

We compared the performance of three different interval types: logit-transformed, probit-transformed, and untransformed (further referred to as the linear interval). We obtain 1,000 draws ("patients") from the prior distribution of pharmacokinetic parameters. For each patient, we simulated 95% confidence intervals for each of the three types using the Metropolis MCMC algorithm.

The posterior coverage of the MIC statistic 95% confidence interval was estimated as follows: one thousand samples were drawn from the prior distribution of PK parameters. For each set of prior parameters, 6 observations were simulated using the concentration predicted by the 4 PK parameters and the standard error term corresponding to the 5th prior parameter. Patients were assumed to receive five 30 minute infusions administered every 8 hours. All observations were simulated during the final (5th) dosing period at 32, 32.5, 33, 34, 36, and 38 hours to evaluate coverage when a patient's response to the drug has achieved a more steady state.

For each of the 1,000 sets of prior parameters and simulated data:

- A Laplace approximation to the posterior density was calculated and the delta method used to estimate the standard errors of the MIC statistic. A 95% asymptotic normal confidence interval was used with the delta method standard errors to estimate upper and lower bounds.
- 3,000 samples from the posterior distribution of PK parameters were taken using a Metropolis MCMC algorithm with 2,000 warm-up iterations. The proportion of the 3,000 posterior samples falling within the upper and lower bounds of the interval was used to estimate the proportion of the posterior distribution of the MIC statistic falling within the confidence interval.

2 Results

2.1 Evaluation of approximation method

On 1,000 samples with a linear interval for $ft > 4 \times MIC$ we calculated a median posterior coverage of 89.7% with an IQR 87.4% to 91.8%. Confidence intervals for the MIC statistic were also considered on the logit and probit scales in order to restrict the bounds to the interval [0,1]; however, as these transformations resulted in slightly lower and more variable posterior coverage, the original scale was used. For the logit-transformed interval, the Bayesian coverage had a median (IQR) of 89.1% (86.5%, 91.2%) and the probit-transformed interval had 89.1% (86.7%, 91.3%).

3 Example

Below we provide an example outlining how to implement this methodology using the pkpredict package. The minimum amount of information required to use the provided functions is the infusion schedule for a given patient of interest. All functions use data only associated with a single patient.

```
# devtools::install_github("hlweeks/pkpredict")
library(pkpredict)
```

3.1 Sample infusion schedule and concentation data

We have a vector of start times for five doses in hours since first infusion, and the duration of each dose. In this case, the duration is the same for each dose: half an hour. The rate of infusion is 6 g/h for all administered doses. Alternatively, the ivt_toList function can take start and end dosing times rather than start times and duration.

```
# Time in hours since first infusion
start_times <- c(0, 8, 16, 24, 32)
# Duration of each infusion in hours
duration <- 0.5
# Rate in g/h
rate_of_infusion <- rep(6, 5)

ivt_d <- ivt_toList(begin = start_times, dur = duration, rate = rate_of_infusion)</pre>
```

We also have sample data from three blood draws, with information on the concentration of piperacillin in the blood in $\mu g/mL$ at the time at which the blood was drawn, again in hours since first infusion.




Figure 1: Comparison of confidence intervals for estimate of target attainment

Plotted values represent the "non-coverage" in each tail region outside the 95% confidence interval. Overall the three types of intervals appear similar in their performance. The transformed intervals more often have higher rates of non-coverage in the lower tail than the upper. Since the intervals have similar performance, in the pkpredict package logit-transformed intervals are used for $ft > 4 \times MIC$ interval computations to enforce the [0,1] bounds.

Table 2: Sample Infusion Schedule

rabie 2. Sample illiasion selleadie					
Begin (h)	End (h)	Infusion Rate (g/h)			
0.0	0.5	6.0			
8.0	8.5	6.0			
16.0	16.5	6.0			
24.0	24.5	6.0			
32.0	32.5	6.0			

Table 3: Sample Data (observed from blood draws)

	\
Time (h)	Concentration (mcg/mL)
1.0	82.7
4.0	80.4
40.0	60.0

3.2 MIC estimates

First, we obtain a prior estimate of target attainment based on the infusion schedule outlined above. By default, the mic_stat function calculates the $fT > 4 \times MIC$, using a threshold of 64 μ g/mL for piperacillin. The dosing window is assumed to end 12 hours after the end of the final infusion, and can be customized if desired.

```
# Threshold is in mcg/mL (same scale as observed data)
# By default, considering time through 12 hours after end of the final dose

# Prior estimate
prior_ft.mic <- mic_stat(ivt = ivt_d, th = 64)
prior_ft.mic

## $ftmic
## [1] 0.4782617
##
## $conf.int
## [1] 0.09186105 0.89255457
##
## attr(,"class")
## [1] "mic" "list"</pre>
```

Without considering patient response from blood draws, the model estimates a patient on this infusion schedule will spend 47.8% (95% CI 9.2% - 89.3%) of their time above the desired threshold. This prior estimate of target attainment represents how we would expect a typical patient to respond to treatment over the course of this infusion schedule, in lieu of any blood concentration measurements. We can incorporate the observed blood draws and obtain an individualized estimate of target attainment based on the patient's data. By adding in concentration measurements from blood draws, we obtain posterior estimates.

```
# Posterior estimate after observed measurements
post_ft.mic <- mic_stat(ivt = ivt_d, dat = dat_d, th = 64)
post_ft.mic
## $ftmic
## [1] 0.7352296
##
## $conf.int
## [1] 0.4755578 0.8947764</pre>
```

```
##
## attr(,"class")
## [1] "mic" "list"
```

Our updated estimate of $ft > 4 \times MIC$ is 73.5% (95% CI 47.6% - 89.5%). By default, the mic_stat function uses the Laplace approximation to calculate an approximate credible interval for target attainment. The user can also specify the argument mcmc = TRUE to use MCMC to obtain a more precise credible interval.

3.3 PK Model

The pkm function fits a two-compartment model to obtain estimates of the concentation-time curve and $ft > 4 \times MIC$.

The model MIC statistic is exactly that produced by the mic_stat function.


Below we extract the predicted concentration values. The estimated concentration of drug in the bloodstream at the supplied start and end of infusion times, and (if applicable) the times associated with concentration measurements from the model.

```
pred.df <- pk.fit$fitted.values
names(pred.df) <- c("Time Since First Infusion (h)", "Concentration (mcg/mL)", "Standard Error")</pre>
```

Table 4: Predicted Values						
Time Since First Infusion (h)	Concentration (mcg/mL)	Standard Error				
0.00	0.20	0.11				
0.50	97.34	0.11				
1.00	91.58	0.10				
4.00	63.51	0.08				
8.00	38.99	0.10				
8.50	134.03	0.09				
16.00	53.68	0.13				
16.50	147.85	0.08				
24.00	59.22	0.14				
24.50	153.07	0.08				
32.00	61.32	0.15				
32.50	155.03	0.08				
40.00	62.11	0.16				

Calling plot on the model object returns a visual representation of the patient's concentration-time curve for the administered drug.

Concentration vs. Time






Figure 2: Screenshot of Shiny application run using shiny_pkm()

Parameter	Value					
$\log(\mu_0)$	$= (lv_1 = 3.223, lk_1 = -1.650, lk_1 = -7, lk_2 = -7)$					
		0.00167	-0.00128	0	0	
∇	$\sim 300 \times$	-0.00128	0.00154	0	0	
\angle_0	~ 500 ×	0	0	.00015	0	ĺ
		0	0	0	.00015)	

Table 5: Prior hyperparameters for piperacillin in a population of hospitalized, critically ill patients.

3.4 Shiny GUI

An interactive implementation of the methods presented here can be launched within the package by calling $shiny_pkm$. This function procudes a web application, created using the shiny package in R. In the application, users can enter information about a patient's infusion schedule and and concentration data collected from blood draws. By default, the application uses the infusion schedule in the example above. There is a checkbox option to allow for computation of the $ft > 4 \times MIC$ credible interval using Markov chain Monte Carlo sampling for an exact interval. This method is more accurate, but takes much longer to perform.

shiny_pkm()

4 Appendix: Prior hyperparameters for piperacillin among critically ill